196 related articles for article (PubMed ID: 37531248)
41. Delivering on the promise of precision cancer medicine.
Berger MF; Van Allen EM
Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
[No Abstract] [Full Text] [Related]
42. [Research progress on genome-guided precision oncology and development ideas of antitumor Chinese medicine].
He SF; Wang M
Zhongguo Zhong Yao Za Zhi; 2023 Mar; 48(6):1421-1430. PubMed ID: 37005829
[TBL] [Abstract][Full Text] [Related]
43. New clinical trial design in precision medicine: discovery, development and direction.
Duan XP; Qin BD; Jiao XD; Liu K; Wang Z; Zang YS
Signal Transduct Target Ther; 2024 Mar; 9(1):57. PubMed ID: 38438349
[TBL] [Abstract][Full Text] [Related]
44. From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development.
Doroshow DB; Doroshow JH
Cancer J; 2019; 25(4):245-253. PubMed ID: 31335388
[TBL] [Abstract][Full Text] [Related]
45. Genomic Alteration-Driven Clinical Trial Designs in Oncology.
Simon R
Ann Intern Med; 2016 Aug; 165(4):270-8. PubMed ID: 27214515
[TBL] [Abstract][Full Text] [Related]
46. Progress in precision therapy in pediatric oncology.
O'Donohue T; Farouk Sait S; Glade Bender J
Curr Opin Pediatr; 2023 Feb; 35(1):41-47. PubMed ID: 36377257
[TBL] [Abstract][Full Text] [Related]
47. Modified study designs to expand treatment options in personalised oncology: a multistakeholder view.
Le Tourneau C; André F; Helland Å; Mileshkin L; Minnaard W; Schiel A; Taskén K; Thomas DM; Veronese ML; Durán-Pacheco G; Leyens L; Rufibach K; Thomas M; Krämer A
Eur J Cancer; 2023 Nov; 194():113278. PubMed ID: 37820553
[TBL] [Abstract][Full Text] [Related]
48. Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection.
De Mattos-Arruda L; Rodon J
Oncologist; 2013; 18(11):1180-8. PubMed ID: 24136009
[TBL] [Abstract][Full Text] [Related]
49. Precision oncology: East meets West.
Subbiah V; Rodon J; Yap TA
Int J Cancer; 2018 May; 142(9):1734-1737. PubMed ID: 29243227
[No Abstract] [Full Text] [Related]
50. Introduction by the Guest Editor: Oncologic Precision Medicine and the Use of Basket and Umbrella Clinical Trials.
Doroshow JH
Cancer J; 2019; 25(4):243-244. PubMed ID: 31335387
[No Abstract] [Full Text] [Related]
51. Strategies For Clinical Implementation: Precision Oncology At Three Distinct Institutions.
Nadauld LD; Ford JM; Pritchard D; Brown T
Health Aff (Millwood); 2018 May; 37(5):751-756. PubMed ID: 29733728
[TBL] [Abstract][Full Text] [Related]
52. The NCI-MATCH trial and precision medicine in gynecologic cancers.
Barroilhet L; Matulonis U
Gynecol Oncol; 2018 Mar; 148(3):585-590. PubMed ID: 29366510
[TBL] [Abstract][Full Text] [Related]
53. Platform trial for off-label oncology drugs using comprehensive genomic profiling under the universal public healthcare system: the BELIEVE trial.
Ishimaru S; Shimoi T; Sunami K; Nakajima M; Ando Y; Okita N; Nakamura K; Shibata T; Fujiwara Y; Yamamoto N
Int J Clin Oncol; 2024 Feb; 29(2):89-95. PubMed ID: 38112833
[TBL] [Abstract][Full Text] [Related]
54. Implementing Precision Medicine Programs and Clinical Trials in the Community-Based Oncology Practice: Barriers and Best Practices.
Ersek JL; Black LJ; Thompson MA; Kim ES
Am Soc Clin Oncol Educ Book; 2018 May; 38():188-196. PubMed ID: 30231363
[TBL] [Abstract][Full Text] [Related]
55. Challenges, opportunities, and innovative statistical designs for precision oncology trials.
Yin J; Shen S; Shi Q
Ann Transl Med; 2022 Sep; 10(18):1038. PubMed ID: 36267789
[TBL] [Abstract][Full Text] [Related]
56. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials.
Hyman DM; Solit DB; Arcila ME; Cheng DT; Sabbatini P; Baselga J; Berger MF; Ladanyi M
Drug Discov Today; 2015 Dec; 20(12):1422-8. PubMed ID: 26320725
[TBL] [Abstract][Full Text] [Related]
57. Precision Medicine in Pediatric Oncology.
Vo KT; Parsons DW; Seibel NL
Surg Oncol Clin N Am; 2020 Jan; 29(1):63-72. PubMed ID: 31757314
[TBL] [Abstract][Full Text] [Related]
58. Pediatric oncology enters an era of precision medicine.
Seibel NL; Janeway K; Allen CE; Chi SN; Cho YJ; Glade Bender JL; Kim A; Laetsch TW; Irwin MS; Takebe N; Tricoli JV; Parsons DW
Curr Probl Cancer; 2017; 41(3):194-200. PubMed ID: 28343740
[TBL] [Abstract][Full Text] [Related]
59. The coming decade in precision oncology: six riddles.
Wahida A; Buschhorn L; Fröhling S; Jost PJ; Schneeweiss A; Lichter P; Kurzrock R
Nat Rev Cancer; 2023 Jan; 23(1):43-54. PubMed ID: 36434139
[TBL] [Abstract][Full Text] [Related]
60. Precision oncology based on omics data: The NCT Heidelberg experience.
Horak P; Klink B; Heining C; Gröschel S; Hutter B; Fröhlich M; Uhrig S; Hübschmann D; Schlesner M; Eils R; Richter D; Pfütze K; Geörg C; Meißburger B; Wolf S; Schulz A; Penzel R; Herpel E; Kirchner M; Lier A; Endris V; Singer S; Schirmacher P; Weichert W; Stenzinger A; Schlenk RF; Schröck E; Brors B; von Kalle C; Glimm H; Fröhling S
Int J Cancer; 2017 Sep; 141(5):877-886. PubMed ID: 28597939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
